MoSAIC Platform
Monolithic Shape-Shifting Absorbable Implants for Chronic Care
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): Brigham and Women's Hospital, MIT
Details
- API: Not Yet Finalized - Tested with Levonorgestrel
- Target: Not Yet Determined - Test Drug Targets Progesterone Receptor
-
Mechanism of Action:
- Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Yet Determined
- Promising Attributes: Developers indicate that final product form may allow for long-term drug dosing, removability for 15+ months and ultimate absorption, and stable, predictable drug release patterns.
Product Status
Active Design & Formulation Refinement
History
2023: Gates Foundation announces $2.7M in funding for Brigham and Women's Hospital, Boston, to develop long-term biodegradable implants for contraception.
2025: Researchers at Brigham and Women's Hospital at Harvard Medical School, the Massachusetts Institute of Technology, the Broad Institute of MIT and Harvard, and the Fenway Institute publish early results evaluating the structure and formulation of a novel monolithic absorbable contraceptive implant, intended to address challenges associated with current implant models. Their proof of concept testing uses LNG, though the drug delivery system is noted as being relevant to other health areas requiring regular dosing.
Publications
doi: 10.1101/2025.05.18.654764